|Bid||43.19 x 800|
|Ask||43.20 x 1100|
|Day's range||42.90 - 43.22|
|52-week range||35.39 - 48.93|
|Beta (3Y monthly)||-0.13|
|PE ratio (TTM)||27.11|
|Forward dividend & yield||0.73 (1.70%)|
|1y target est||52.50|
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses...
Smith & Nephew plc (LON:SN.) is about to trade ex-dividend in the next 2 days. If you purchase the stock on or after...
Is Smith & Nephew plc (LON:SN.) a good dividend stock? How can we tell? Dividend paying companies with growing...
Examining how Smith & Nephew plc (LON:SN.) is performing as a company requires looking at more than just a years...
Looking at Smith & Nephew plc's (LON:SN.) earnings update in December 2018, it seems that analyst forecasts are fairly...
With Smith & Nephew's (SNN) buyout of Atracsys, the latter's fusionTrack 500 optical tracking camera will be a core enabling technology for the company's next-generation robotics platform.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
The transaction by Smith & Nephew (SNN), besides the business purchase, comprises certain intangible assets and the orthopaedic Brainlab salesforce.
Titan Medical (TMDI) is putting in a good deal of effort to strengthen its position in the multi-billion dollar computer-assisted robotic surgical technologies market.
Attractive stocks have exceptional fundamentals. In the case of Smith & Nephew plc (LON:SN.), there's is a notable dividend-paying company that has been able to sustain great financial health over t...